Latest news with #zanubrutinib
The Herald Scotland
11-08-2025
- Health
- The Herald Scotland
Three new cancer drugs approved for use for NHS Scotland
However, the SMC did approve the drug brentuximab vedotin, also known as Adcetris, to be used together with chemotherapy as a first-line treatment for adult patients with advanced Hodgkin lymphoma – an uncommon cancer that develops in the lymphatic system. SMC vice chair Graeme Bryson said the treatment could 'help increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse'. Meanwhile, zanubrutinib, also known as Brukinsa, was accepted to treat adults with mantle cell lymphoma – a rare type of the blood cancer non-Hodgkin lymphoma. READ MORE: The SMC has also approved the drug ripretinib – also known as Qinlock – to treat adults with advanced gastrointestinal stromal tumours, which are a rare type of cancer of the digestive system. In addition to these drugs it has agreed the NHS can use mirikizumab, also known as Omvoh, for adults with Crohn's disease, a lifelong condition which is a chronic inflammatory bowel disease. However, the SMC rejected the drug dupilumab, also known as Dupixent, as a treatment on the NHS for adults with COPD that is controlled on current standard treatments. Mr Bryson said: 'The committee is pleased to be able to accept these new medicines for use by NHS Scotland. 'Brentuximab vedotin, used together with chemotherapy, could help increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse. 'Ripretinib provides a fourth-line treatment for advanced gastro-intestinal stromal tumours where currently there is no standard treatment available. 'Zanubrutinib offers an additional oral targeted treatment option for patients with mantle cell lymphoma who have already received one or more lines of treatment. 'Mirikizumab offers an additional treatment option for people with moderate to severe Crohn's disease whose disease is not controlled on standard or biologic treatment.' However he added: 'The committee was unable to accept dupilumab for treating patients with COPD as the company's evidence around the cost-effectiveness of the treatment was not sufficient. We would welcome a resubmission from the company.'
Mint
09-06-2025
- Business
- Mint
Glenmark to launch cancer drug Zanubrutinib in India
New Delhi: Glenmark Pharmaceuticals on Monday said it will launch cancer treatment drug zanubrutinib in India following approval by the Drugs Controller General of India (DCGI). Zanubrutinib will be marketed in India under the brand name Brukinsa. It is the first and only Bruton's tyrosine kinase (BTK) inhibitor approved in India for the treatment of five distinct B-cell malignancies: chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom macroglobulinemia, mantle cell lymphoma, marginal zone lymphoma, and follicular lymphoma. "We look forward to bringing Brukinsa to India in the coming months as part of our ongoing partnership with BeiGene (now BeOne Medicines)," Glenmark Pharmaceuticals President and Business Head - India Formulations Alok Malik said. The launch marks a significant milestone in our innovative oncology portfolio, offering patients in India access to a globally trusted therapy with proven efficacy and safety, he added. Glenmark shares on Monday ended 0.68 per cent up at ₹ 1,600.85 apiece on BSE. In March, Glenmark Pharmaceuticals had launched a medication for glycemic control and weight-loss for diabetes patients. The Mumbai-based drug firm launched Empagliflozin, a widely recognised SGLT2 inhibitor, under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)''Glempa-L (Empagliflozin 10/25 mg Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg Metformin 500/1000 mg). The medications are designed to improve glycemic control in adults with type 2 diabetes mellitus while also reducing cardiovascular outcomes in patients with cardiovascular risk. Studies have demonstrated several benefits of Empagliflozin, including effectively improving glycemic control, supporting weight-loss, and reducing cardiovascular-renal risks in patients with type 2 diabetes mellitus. Empagliflozin has also demonstrated benefits in heart failure patients by lowering the cardiovascular death or hospitalisation. "The launch of Glempa range reinforces this commitment by providing a comprehensive and affordable solution that empowers healthcare professionals and patients to manage type 2 diabetes mellitus with established cardiovascular disease more effectively," Glenmark Pharmaceuticals President and Head of India Formulations Business Alok Malik had said.
Time of India
09-06-2025
- Business
- Time of India
Glenmark to launch DCGI-approved cancer drug in India
Glenmark Pharmaceuticals on Monday said it will launch cancer treatment drug zanubrutinib in India following approval by the Drugs Controller General of India ( DCGI ). Zanubrutinib will be marketed in India under the brand name Brukinsa . It is the first and only Bruton's tyrosine kinase (BTK) inhibitor approved in India for the treatment of five distinct B-cell malignancies: chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom macroglobulinemia, mantle cell lymphoma, marginal zone lymphoma, and follicular lymphoma. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Bank Owned Properties For Sale In Larantuka (Prices May Surprise You) Foreclosed Homes | Search ads Search Now Undo "We look forward to bringing Brukinsa to India in the coming months as part of our ongoing partnership with BeiGene (now BeOne Medicines)," Glenmark Pharmaceuticals President and Business Head - India Formulations Alok Malik said. The launch marks a significant milestone in our innovative oncology portfolio, offering patients in India access to a globally trusted therapy with proven efficacy and safety, he added. Glenmark shares on Monday ended 0.68 per cent up at Rs 1,600.85 apiece on BSE.
